Our goal:
Each year, millions suffer from cardiac arrest and hundreds of thousand of children suffer from neonatal asphyxia (lack of oxygen at birth). To minimise the harm from this, external or internal cooling is used, activating the mild hypothermia response, a detailed and highly regulated process in the body.
Our goal is to
- Understand the genetic background of the mild hypothermia response
- Identify suitable biomarkers
- Develop medications to manipulate the mild hypothermia response
- With the overall goal of maximising the use of the mild hypothermia response to patients in need
Our Institutions and investors
All
-
Kaldur closes angel investment round
Kaldur therapeutics has just closed an investment round following investment by Kría Innovation fund. The investment from Kría was contingent on matching funds from angel investors. The total investment from the round is 49 million ISK (350 thousand USD).
-
Kaldur recognized as a national healthtech leader
The Nelson advisors consulting firm just released its list of twenty future leaders within Icelandic healthtech and medtech – and Kaldur is number 7 – we are grateful for the recognition! https://www.healthcare.digital/single-post/20-future-icelandic-healthtech-and-medtech-leaders
-
Dr. Björnsson receives grant of excellence
Dr. Björnssons lab at the University of Iceland has just received a grant of excellence (öndvegisstyrkur) from Rannis, the Icelandic Research Fund. The grant is for 60 million ISK (500 thousand USD) per year for 3 years. The grant will be used to further understand the molecular mechanism of hypothermia.
KALDUR Therapeutics 